Harvard Apparatus Regenerative Technology Files Pre-IND Meeting Documents And Orphan Biologics Application With U.S. FDA
Published: Jan 06, 2014
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has filed its pre-Investigational New Drug (IND) meeting documents with the U.S. Food and Drug Administration (FDA). The company expects the pre-IND meeting to take place by the end of January 2014.
Help employers find you! Check out all the jobs and post your resume.